# Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer

> **NCT03286244** · PHASE1 · UNKNOWN · sponsor: **AnewPharma** · enrollment: 21 (estimated)

## Conditions studied

- Advanced Gastric Cancer

## Interventions

- **DRUG:** CM082 plus paclitaxel

## Key facts

- **NCT ID:** NCT03286244
- **Lead sponsor:** AnewPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-15
- **Primary completion:** 2019-08
- **Final completion:** 2020-08
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2019-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03286244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03286244, "Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03286244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*